<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907294</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-PBF-2015-82</org_study_id>
    <secondary_id>2015-004748-20</secondary_id>
    <nct_id>NCT02907294</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 &quot;After Multiple Oral Doses&quot; in Healthy Volunteers</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) &quot;After Multiple Oral Doses&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palobiofarma SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Palobiofarma SL</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of five doses of PBF-999 (160 mg and 320mg) after
      repeated (8 days) single daily oral dose administration in young male and female healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    change in the therapeutic indication
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>from day 0 to day 15</time_frame>
    <description>Vital Signs, ECG recordings, laboratory safety test and physical examination will be performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>from day 1 to 8</time_frame>
    <description>Day 1: baseline [pre-dose], [+10 min], [+20 min], [+40min], [+60min], [+ 1.5h], [+2 h], [+ 2.5 h], [+ 3 h], [+ 4h], [+8h], [+ 12h] and [+16h] post-medication;
Days 2 to 7: baseline [daily pre-dose] which corresponds at +24h of previous dose;
Day 8: baseline [daily pre-dose], [+10 min], [+20 min], [+40min], [+60min], [+1.5h], [+2 h], [+ 2.5 h], [+ 3 h], [+ 4h], [+8h], [+ 12h] and [+16h] and [+ 24h] post-daily medication (D9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>from day 1 to 8</time_frame>
    <description>Day 1: baseline [pre-dose], [+10 min], [+20 min], [+40min], [+60min], [+ 1.5h], [+2 h], [+ 2.5 h], [+ 3 h], [+ 4h], [+8h], [+ 12h] and [+16h] post-medication;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Leeds Sleep Evaluation Questionnaire</measure>
    <time_frame>from day 1 to 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>-Analogic visual scales (VAS/100)</measure>
    <time_frame>from day 1 to 8</time_frame>
    <description>ten scales will be used, Liking (only at +24 of the last drug administration), high, good effects, bad effects, sedation, nervous, euphoria, absent, vigouros and aphatetic.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>PBF-999</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBF-999 / 160 mg</intervention_name>
    <description>2 capsule 80 mg x 8 days</description>
    <arm_group_label>PBF-999</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBF-999 / 320 mg</intervention_name>
    <description>4 capsule 80 mg x 8 days</description>
    <arm_group_label>PBF-999</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules of placebo x 8 days 4 capsules of placebo x 8 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or females subjects, 18-45 years (inclusive) of age at the time of
             enrollment.

          -  Females must be of non-childbearing potential (i.e., surgically sterile) or have to
             use contraceptive measures (non-hormonal) such as condom, diaphragm or cervical/vault
             cap with spermicide until 28 days post-administration. Males should agree to abstain
             from sexual intercourse with a female partner or agree to use a condom with
             spermicide, in addition to having their female partner use some contraceptive measures
             until 28 days post-administration.

          -  Clinically acceptable blood pressure and pulse rate in supine and standing position.
             Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.

          -  Body weight within normal range (Quetelet's index between 19 and 26) expressed as
             weight (kg) / height (m2).

          -  Able to understand the nature of the study and comply with all their requirements.

          -  Free acceptance to participate in the study by obtains signed informed consent form
             approved by the Ethics Committee of the Hospital (CEIC).

        Exclusion Criteria:

          -  History of serious adverse reactions or hypersensitivity to any drug.

          -  Presence or history of allergies requiring acute or chronic treatment (except seasonal
             allergic rhinitis).

          -  Background or clinical evidence of chronic diseases.

          -  Acute illness two weeks before drug administration.

          -  Having undergone major surgery during the previous 6 months.

          -  Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine
             patches, etc., for 6 months prior to the administration of the study medication

          -  History of alcohol dependence or drug abuse in the last 5 years or daily consumption
             of alcohol &gt; 40 g for men or 24 gr/day for women or high consumption of stimulating
             beverages (&gt; 5 coffees, teas or coca cola drinks/ day)

          -  Abnormal physical findings of clinical significance at the screening examination or
             baseline which would interfere with the objectives of the study.

          -  Need of any prescription medication within 14 days prior to the administration of the
             drug and non prescription medication or herbal medicines within 7 days prior to the
             administration of the drug.

          -  Participation in other clinical trials during the previous 90 days in which an
             investigational drug or a commercially available drug was tested.

          -  Having donated blood during 4 weeks period before inclusion in the study.

          -  Existence of any surgical or medical condition which might interfere with the
             absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or
             hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of
             pronounced constipation or diarrhea or conditions associated with total or partial
             obstruction of the urinary tract.

          -  12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440
             msec, bradychardia (&lt;50 bpm) or clinically significant minor ST wave changes or any
             other abnormal changes on the screening ECG that would interfere with measurement of
             the QT interval.

          -  Symptoms of a significant somatic or mental illness in the four week period preceding
             drug administration.

          -  History of hepatitis HBV and / or HCV and / or positive serology results which
             indicate the presence of hepatitis B surface antigen and / or detectable HCV
             ribonucleic acid (RNA).

          -  Positive results from the HIV serology.

          -  Females with positive results from the pregnancy test or breast-feeding

          -  Clinically significant abnormal laboratory values (as determined by the Principal
             Investigator) at the screening evaluation.

          -  Positive results of the drugs at screening period or the day before starting treatment
             period. A minimum list of drugs that will be screened for include Amphetamines,
             Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be
             repeated at the discretion of the Principal Investigator).

          -  Known hypersensitivity to the study drug or the composition of the galenical form

          -  History of psychiatric diseases or epileptic seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIM-Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIM-Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.iibsantpau.cat/</url>
    <description>phase 1 unit website</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDE10 inhibitor</keyword>
  <keyword>phosphodiesterase 10 inhibitor</keyword>
  <keyword>Huntington's disease</keyword>
  <keyword>psychiatric disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

